Big data analysis and visualization platform in cell engineering research—Intelligent analysis method based on mechanical properties and cellular interactions
Abstract
This research presents a comprehensive big data analysis and visualization platform specifically designed for cancer cell engineering, with a primary focus on understanding the mechanical properties and interactions of cancer cells, particularly in the context of ABC transporter-mediated drug resistance mechanisms in breast and lung cancer cells. The platform integrates advanced machine learning algorithms with real-time analysis capabilities of cellular mechanics and interactive visualization techniques, addressing critical challenges in cellular biomechanics visualization and multi-dimensional data integration. To strengthen its relevance, specific case studies are included that demonstrate the platform’s practical applications in biomechanics research, such as analyzing cell movement, mechanical properties, and cell-cell interactions. The integration of biomechanical models with the platform’s analysis tools is discussed to enhance the understanding of cellular behaviors. Comparative analysis with existing cellular visualization systems demonstrates significant improvements in data processing capabilities and analytical accuracy, particularly in correlating processed data with biomechanics-related metrics like cellular stress and deformation. The system’s performance has been extensively validated across multiple experimental scenarios. Algorithm accuracy achieved 98.5% in feature extraction and 97.9% in pattern recognition tasks, specifically in identifying patterns related to ABC transporter-mediated drug resistance. The platform’s distributed architecture demonstrated exceptional scalability, maintaining stable performance with up to 5000 concurrent research users while achieving 88.4% resource efficiency—a significant advancement over current cellular analysis platforms. Integration testing confirmed robust interoperability between analytical modules with a 99.8% success rate in analyzing cellular transport mechanisms. Stress testing revealed sustained system stability under loads up to 175% of designed capacity, with graceful degradation beyond this threshold. Validation experiments across diverse cancer cell analysis scenarios yielded a 98.8% success rate with statistical significance (p < 0.001). The platform introduces novel approaches to cellular transport visualization, particularly in analyzing ABC transporter activity, offering real-time interactive 3D visualization capabilities not available in existing systems. This platform significantly advances the field of cell engineering data analysis by providing a reliable, scalable, and efficient solution for complex biological data processing and visualization, specifically addressing the challenges in cancer cell research, mechanical properties analysis, and drug resistance.
References
1. Aguirre-Portoles C, Fernandez LP, Ramirez de Molina A, Ramos-Ruiz R, Birtus M, & Martinez-Torrecuadrada JL. (2018). ABCA1 overexpression worsens colorectal cancer prognosis by facilitating tumour growth and caveolin-1-dependent invasiveness, and these effects can be ameliorated using the BET inhibitor apabetalone. Molecular Oncology, 12(10), 1735-1752.
2. Barakat S, Demeule M, Pilorget A, Regina A, Gingras D, Baggetto LG, & Beliveau R. (2008). Regulation of brain endothelial cells migration and angiogenesis by P-glycoprotein/caveolin-1 interaction. Biochemical and Biophysical Research Communications, 372(3), 440-446.
3. Bhattacharya R, Mondal R, & Sharma P. (2022). CFTR and gastrointestinal cancers: an update. Journal of Personalized Medicine, 12(6), 868.
4. Castiglioni S, Monti M, Arnaboldi L, Canavesi M, Ainis Buscherini G, Calabresi L, & Corsini A. (2017). ABCA1 and HDL(3) are required to modulate smooth muscle cells phenotypic switch after cholesterol loading. Atherosclerosis, 266, 8-15.
5. Chen Z, Liu F, Ren Q, Zhao Q, Ren H, Lu S, & Liang P. (2010). Suppression of ABCG2 inhibits cancer cell proliferation. International Journal of Cancer, 126(4), 841-851.
6. Ding XW, Wu JH, & Jiang CP. (2010). ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sciences, 86(17-18), 631-637.
7. Dong H, Li J, Wang X, Zhang Y, Yang Q, & Chen Y. (2021). Exosomal miR-4488 and miR-1273g-5p inhibit the epithelial-mesenchymal transition of transforming growth factor β2-mediated retinal pigment epithelial cells by targeting ATP-binding cassette A4. Bioengineered, 12(1), 9693-9706.
8. Duvivier L, & Gillet JP. (2022). Deciphering the roles of ABCB5 in normal and cancer cells. Trends in Cancer, 8(9), 795-798.
9. Fung SW, Cheung PF, Yip CW, Ng LW, Cheung TT, Chong CC, & Wong N. (2019). The ATP-binding cassette transporter ABCF1 is a hepatic oncofetal protein that promotes chemoresistance, EMT and cancer stemness in hepatocellular carcinoma. Cancer Letters, 457, 98-109.
10. Gauthier C, Ozvegy-Laczka C, Szakacs G, Sarkadi B, & Di Pietro A. (2013). ABCG2 is not able to catalyze glutathione efflux and does not contribute to GSH-dependent collateral sensitivity. Frontiers in Pharmacology, 4, 138.
11. Hanahan D. (2022). Hallmarks of cancer: new dimensions. Cancer Discovery, 12(1), 31-46.
12. Hanouna G, Mesnage S, Petit L, Mansuet-Lupo A, Boiteux C, Jacobelli S, & Tartour E. (2020). Preventing calpain externalization by reducing ABCA1 activity with probenecid limits melanoma angiogenesis and development. Journal of Investigative Dermatology, 140(2), 445-454.
13. Issitt T, Bosseboeuf E, De Winter N, Dufton N, Gestri G, Senatore V, & Raimondi C. (2019). Neuropilin-1 controls endothelial homeostasis by regulating mitochondrial function and iron-dependent oxidative stress. iScience, 11, 205-223.
14. Jiang M, Le TT, Yang C, Hudson BM, Hassler JR, Liu X, & Zhang JT. (2021). VEGF receptor 2 (KDR) protects airways from mucus metaplasia through a Sox9-dependent pathway. Developmental Cell, 56(11), 1646-1660.e5.
15. Johnsen AK, Templeton DJ, Sy MS, & Harding CV. (1999). Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. Journal of Immunology, 163(8), 4224-4431.
16. Kim JY, Hwang JH, Zhou W, Shin J, Noh SM, Song IS, & Cho JY. (2020). ABCB7 simultaneously regulates apoptotic and non-apoptotic cell death by modulating mitochondrial ROS and HIF1alpha-driven NFkappaB signaling. Oncogene, 39(9), 1969-1982.
17. Kondo S, Ikeda T, Sasaki H, Kakeya H, Fukushima K, & Mukae H. (2020). STAT1 upregulates glutaminase and modulates amino acids and glutathione metabolism. Biochemical and Biophysical Research Communications, 523(3), 672-677.
18. Kuss BJ, Corbo M, Lau WM, Fennell DA, Dean NM, & Cotter FE. (2002). In vitro and in vivo downregulation of MRP1 by antisense oligonucleotides: a potential role in neuroblastoma therapy. International Journal of Cancer, 98(1), 128-133.
19. Leslie EM, Deeley RG, & Cole SP. (2001). Transport of the beta-O-glucuronide conjugate of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by the multidrug resistance protein 1 (MRP1). Requirement for glutathione or a non-sulfur-containing analog. Journal of Biological Chemistry, 276(30), 27846-27854.
20. Leslie EM, Ito K, Upadhyaya P, Hecht SS, Deeley RG, & Cole SP. (2007). Biotransformation and transport of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in bile duct-cannulated wild-type and Mrp2/Abcc2-deficient (TR) Wistar rats. Carcinogenesis, 28(12), 2650-2656.
21. Liao Z, Chua D, & Tan NS. (2019). Reactive oxygen species: a volatile driver of field cancerization and metastasis. Molecular Cancer, 18, 65.
22. Ling A, Löfgren-Burström A, Larsson P, Li X, Wikberg ML, Öberg Å, & Palmqvist R. (2017). TAP1 down-regulation elicits immune escape and poor prognosis in colorectal cancer. OncoImmunology, 6(1), e1356143.
23. Liu X, Gong H, & Li C. (2016). Overexpression of ABCC3 promotes cell proliferation, drug resistance, and aerobic glycolysis and is associated with poor prognosis in urinary bladder cancer patients. Tumour Biology, 37(6), 8367-8374.
24. Lv C, Xu J, Wang Y, Zhang L, & Zhang J. (2022). ABCA8 inhibits breast cancer cell proliferation by regulating the AMP activated protein kinase/mammalian target of rapamycin signaling pathway. Environmental Toxicology, 37(6), 1423-1431.
25. Ma L, Wang L, Nelson AT, Han C, He S, Henn MA, & McDonnell DP. (2020). 27-Hydroxycholesterol acts on myeloid immune cells to induce T cell dysfunction, promoting breast cancer progression. Cancer Letters, 493, 266-283.
26. Mantel I, Erika K, & Van den Eynde BJ. (2022). Spotlight on TAP and its vital role in antigen presentation and cross-presentation. Molecular Immunology, 142, 105-119.
27. Marchan R, Hammond CL, & Ballatori N. (2008). Multidrug resistance-associated protein 1 as a major mediator of basal and apoptotic glutathione release. Biochimica et Biophysica Acta, 1778(10), 2413-2420.
28. Miglionico R, Ostuni A, Armentano MF, Milella L, Crescenzi E, Carmosino M, & Bisaccia F. (2017). ABCC6 knockdown in HepG2 cells induces a senescent-like cell phenotype. Cellular and Molecular Biology Letters, 22, 7.
29. Mijac D, Bojic D, Jankovic GL, Milutinovic SS, Krstic M, Markovic M, & Popovic D. (2018). MDR1 gene polymorphisms are associated with ulcerative colitis in a cohort of Serbian patients with inflammatory bowel disease. PLoS One, 13(3), e0194536.
30. Moon SH, Huang CH, Houlihan SL, Regunath K, Freed-Pastor WA, Morris JP, & Prives C. (2019). p53 represses the mevalonate pathway to mediate tumor suppression. Cell, 176(3), 564-580.e19.
31. Mullen PJ, Yu R, Longo J, Archer MC, & Penn LZ. (2016). The interplay between cell signalling and the mevalonate pathway in cancer. Nature Reviews Cancer, 16(11), 718-731.
32. Murray J, Valli E, Yu DM. T., Truong AM, Gifford AJ, Eden GL, & Henderson MJ. (2017). Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivo. European Journal of Cancer, 83, 132-141.
33. Nones K, Knoch B, Dommels YE, Paturi G, Butts C, McNabb WC, & Roy NC. (2009). Multidrug resistance gene deficient (mdr1a−/−) mice have an altered caecal microbiota that precedes the onset of intestinal inflammation. Journal of Applied Microbiology, 107(2), 557-566.
34. Ooi CY, & Durie PR. (2012). Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in pancreatitis. Journal of Cystic Fibrosis, 11(5), 355-362.
35. Ostuni A, Miglionico R, Carmosino M, Dragonetti A, Laricchia R, Bisaccia F, & Castiglione Morelli MA. (2020). Inhibition of ABCC6 transporter modifies cytoskeleton and reduces motility of HepG2 cells via purinergic pathway. Cells, 9(6), 1410.
36. Ou HL, Schumacher B. (2021). Cellular senescence in cancer: from mechanisms to detection. Molecular Oncology, 15(10), 2634-2671.
37. Panwala CM, Jones JC, & Viney JL. (1998). A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. Journal of Immunology, 161(10), 5733-5744.
38. Paul VD, & Lill R. (2015). Biogenesis of cytosolic and nuclear iron-sulfur proteins and their role in genome stability. Biochimica et Biophysica Acta, 1853(6), 1528-1539.
39. Polireddy K, Chavan H, Abdulkarim BA, & Krishnamurthy P. (2011). Functional significance of the ATP-binding cassette transporter B6 in hepatocellular carcinoma. Molecular Oncology, 5(4), 410-425.
40. Quaresma MC, Pankonien I, Clarke LA, Sousa LS, Silva IA. L., Railean V, & Amaral MD. (2020). Mutant CFTR drives TWIST1 mediated epithelial-mesenchymal transition. Cell Death & Disease, 11(10), 920.
41. Sahores A, May M, Sequeira GR, Fuentes C, Jacobsen B, Lanari C, & Lamb CA. (2020). Multidrug transporter MRP4/ABCC4 as a key determinant of pancreatic cancer aggressiveness. Scientific Reports, 10(1), 14217.
42. Sana G, Malaponte G, Dugo M, De Cecco L, Casalini P, & De Luca V. (2019). Exome sequencing of ABCB5 identifies recurrent melanoma mutations that result in increased proliferative and invasive capacities. Journal of Investigative Dermatology, 139(9), 1985-1992.e10.
43. Seres L, Cserepes J, Elkind NB, Torocsik D, Nagy L, Sarkadi B, & Homolya L. (2008). Functional ABCG1 expression induces apoptosis in macrophages and other cell types. Biochimica et Biophysica Acta, 1778(10), 2378-2387.
44. Shaffer BC, Gillet JP, Patel C, Baer MR, Bates SE, & Gottesman MM. (2012). Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resistance Updates, 15(1-2), 62-69.
45. Tagami M, Kusuhara S, Honda S, Tsukahara Y, & Negi A. (2010).
46. Tagami M, Kusuhara S, Honda S, Tsukahara Y, & Negi A. (2010). MRP4 knockdown enhances migration, suppresses apoptosis, and produces aggregated morphology in human retinal vascular endothelial cells. Biochemical and Biophysical Research Communications, 400(4), 593-598.
47. Tian Y, Tian X, Han X, Chen Y, Song CY, Jiang WJ, & Tian DL. (2016). ABCE1 plays an essential role in lung cancer progression and metastasis. Tumour Biology, 37(7), 8375-8382.
48. Vlaming ML, van Esch A, Poot M, Lagas JS, van de Steeg E, de Waart DR, & Schinkel AH. (2014). Bcrp1;Mdr1a/b;Mrp2 combination knockout mice: altered disposition of the dietary carcinogen PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) and its genotoxic metabolites. Molecular Pharmacology, 85(3), 520-530.
49. Wang J, Xu J, Li G, Zhang Z, Liu Y, Wang B, & Jin H. (2017). ABCG2 confers promotion in gastric cancer through modulating downstream CRKL in vitro combining with biostatistics mining. Oncotarget, 8(4), 5256-5267.
50. Wang R, Sheps JA, & Ling V. (2022). ABC transporters, bile acids, and inflammatory stress in liver cancer. Current Pharmaceutical Biotechnology, 12(5), 636-646.
51. Wee B, Pietras A, Ozawa T, Bazzoli E, Podlaha O, Antczak C, & Holland EC. (2016). ABCG2 regulates self-renewal and stem cell marker expression but not tumorigenicity or radiation resistance of glioma cells. Scientific Reports, 6, 25956.
52. Wiel C, Lallet-Daher H, Gitenay D, Gras B, Le Calve B, Augert A, & Bernard D. (2016). Multidrug resistance protein 3 loss promotes tumor formation by inducing senescence escape. Oncogene, 35(12), 1596-1601.
53. Wilson BJ, Saab KR, Ma J, Schatton T, Putz P, Zhan Q, & Frank MH. (2014). ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit. Cancer Research, 74(15), 4196-4207.
54. Xie C, Jiang XH, Zhang JT, Sun TT, Dong JD, Sanders AJ, & Guo XL. (2013). CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer. Oncogene, 32(18), 2282-2291.
55. Xie J, Li DW, Chen XW, Wang F, & Dong P. (2014). ABCG2 regulated by MAPK pathways is associated with cancer progression in laryngeal squamous cell carcinoma. American Journal of Cancer Research, 4(6), 698-709.
56. Xu J, Yang Y, Xie R, Liu J, Nie X, An J, & Wen G. (2015). High level of CFTR expression is associated with tumor aggression and knockdown of CFTR suppresses proliferation of ovarian cancer in vitro and in vivo. Oncology Reports, 33(5), 2227-2234.
57. Xu K, Liu X, Yang Y, He Y, Zhang L, Cao Y, & Lin J. (2019). Glibenclamide targets sulfonylurea receptor 1 to inhibit p70S6K activity and upregulate KLF4 expression to suppress non-small cell lung carcinoma. Molecular Cancer Therapeutics, 18(11), 2085-2096.
58. Yamada A, Nagahashi M, Aoyagi T, Huang WC, Lima S, Hait NC, & Takabe K. (2018). ABCC1-exported sphingosine-1-phosphate, produced by sphingosine kinase 1, shortens survival of mice and patients with breast cancer. Molecular Cancer Research, 16(6), 1059-1070.
Copyright (c) 2025 Author(s)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright on all articles published in this journal is retained by the author(s), while the author(s) grant the publisher as the original publisher to publish the article.
Articles published in this journal are licensed under a Creative Commons Attribution 4.0 International, which means they can be shared, adapted and distributed provided that the original published version is cited.
Submit a Paper
